TLR8 and chronic hepatitis B virus infection: The TLR8 agonist GS-9688 (selgantolimod) was discovered as a potent and selective oral TLR8 agonist for the treatment of chronic hepatitis B. In a preclinical study, a reduction in viral markers was observed in HBV-infected primary human hepatocytes treated with GS-9688 [171].